Valuation: Genovis AB

Market Cap 1.53B 150M 137M 126M 115M 215M 13.91B 226M 610M 7.6B 564M 552M 23.85B P/E 2026 *
84.3x
P/E 2027 * 44.6x
Enterprise Value 1.42B 139M 127M 117M 106M 200M 12.91B 210M 566M 7.05B 523M 512M 22.12B EV / Sales 2026 *
9.89x
EV / Sales 2027 * 7.41x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day-2.78%
1 week-3.60%
Current month+5.08%
1 month+10.17%
3 months+13.18%
6 months+12.35%
Current year+7.06%
1 week 22
Extreme 22
24
1 month 20.05
Extreme 20.05
24.55
Current year 15.64
Extreme 15.64
24.55
1 year 15.64
Extreme 15.64
24.55
3 years 15.64
Extreme 15.64
53.9
5 years 15.64
Extreme 15.64
77.5
10 years 2.18
Extreme 2.18
90
Manager TitleAgeSince
Chief Executive Officer 55 2015-05-04
Director of Finance/CFO 42 2026-07-31
Chief Tech/Sci/R&D Officer 42 2016-12-31
Director TitleAgeSince
Director/Board Member 77 2013-12-31
Director/Board Member 65 2018-12-31
Chairman 74 2020-05-04
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 Buy 6,648 0.0101%
10/1/26 Buy

Chairman

45,000 0.0681%
9/30/26 Buy

Chief Executive Officer

28,000 0.0424%
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%-3.60%+13.75%-50.44% 150M
-0.84%-5.09%-19.60%+1.07% 178B
-0.67%-2.84%-1.25%+27.12% 122B
-0.98%+0.12%-15.82%+5.56% 118B
-1.24%-4.25%-42.94%-1.34% 88.1B
-0.63%-5.55%-7.27%+70.54% 64.71B
+0.05%-2.41%+10.41%-9.90% 57.96B
-1.95%-3.98%-6.85%+41.55% 53.28B
-2.91%-4.35%-0.97%+38.45% 47.8B
-1.64%+1.50%+1.30%-2.04% 35.65B
Average -1.36%-2.72%-6.92%+12.06% 77B
Weighted average by Cap. -1.04%-2.97%-12.43%+15.67%

Financials

2026 *2027 *
Net sales 144M 14.09M 12.84M 11.83M 10.76M 20.18M 1.31B 21.21M 57.21M 713M 52.88M 51.76M 2.24B 187M 18.35M 16.71M 15.4M 14.01M 26.28M 1.7B 27.62M 74.5M 928M 68.86M 67.4M 2.91B
Net income 15.8M 1.55M 1.41M 1.3M 1.18M 2.22M 143M 2.33M 6.28M 78.24M 5.8M 5.68M 246M 34.9M 3.42M 3.11M 2.87M 2.61M 4.89M 316M 5.14M 13.87M 173M 12.82M 12.55M 542M
Net Debt -111M -10.87M -9.9M -9.12M -8.3M -15.56M -1.01B -16.36M -44.12M -550M -40.77M -39.91M -1.72B -146M -14.29M -13.02M -12M -10.91M -20.47M -1.32B -21.51M -58.03M -723M -53.63M -52.5M -2.27B
Projected Income Statement - Annual - Genovis AB
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
43
Date Price Change Volume
26-11-20 SEK 22.75 -2.78% 100,027
26-11-19 SEK 23.40 +4.00% 173,246
26-11-18 SEK 22.50 0.00% 160,039
26-11-17 SEK 22.50 -4.46% 114,325
26-11-16 SEK 23.55 -0.21% 129,297
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Genovis AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
22.75SEK
Average target price
34.00SEK
Spread / Average Target
+49.45%
  1. Stock Market
  2. Stocks
  3. GENO Stock